Vitamin K2 supplement tested as new migraine treatment

NCT ID NCT05943457

Recruiting now Symptom relief Sponsor: Sola Aoun Bahous, M.D. Ph.D. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether taking vitamin K2 supplements daily for 6 months can reduce the number of migraine days in adults with episodic migraine. Researchers will also measure if it improves artery stiffness, which is often higher in people with migraines. 160 participants will be randomly assigned to receive either vitamin K2 or a placebo pill.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Vitamin K2 (menaquinone-7) supplement
What this could lead to: If it works, this could offer a simple, low-cost supplement to reduce migraine frequency and improve blood vessel health.
What could go wrong: This is an early-stage trial with 160 people, so results may not apply to everyone. Supplements can have side effects, and the benefit over placebo may be small or none.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARTERIAL STIFFNESS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

migraine disorder vitamin K deficiency hemorrhagic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARTERIAL STIFFNESS MIGRAINE HEADACHE VITAMIN K DEFICIENCY

Contacts and locations

Locations

Lebanese American University Medical Center - Rizk Hospital
RECRUITING

Beirut, Beirut, 11-3288, Lebanon

More trials for these conditions

Other studies related to the condition(s) this trial covers.